Nanoparticles Overcome Anticancer Drug Resistance

Jun 12, 2006

Too often, chemotherapy fails to cure cancer because some tumor cells develop resistance to multiple anticancer drugs. In most cases, resistance develops when cancer cells begin expressing a protein, known as p-glycoprotein, that is capable of pumping anticancer drugs out of a cell as quickly as they cross through the cell’s outer membrane. New research from the University of Kentucky shows that nanoparticles may be able to get anticancer drugs into cells without triggering the p-glycoprotein pump.

Writing in the Journal of Controlled Release, a team led by Russell Mumper, Ph.D., describes its work using untargeted nanoparticles made of cetyl alcohol and polysorbate, which the investigators have named E78 nanoparticles, as a delivery vehicle for the potent anticancer drug paclitaxel. Biodistribution studies with the formulation and with free paclitaxel revealed few significant differences in which the active drug ends up in the body.

Next, the investigators injected the nanoparticle-entrapped paclitaxel, empty nanoparticles, free paclitaxel, or saline directly into paclitaxel-resistant human colon tumors growing in mice. Nineteen days after injection, tumors in the animals treated with nanoparticle-entrapped paclitaxel were 47 percent smaller than those treated with free paclitaxel and 70 percent smaller than those in animals treated with plain nanoparticles or saline.

One surprising finding from this study was the fact that free paclitaxel had any effect at all on tumors known to be resistant to the drug. Further investigation showed that this effect was likely a result of paclitaxel’s ability to inhibit angiogenesis. The researchers concluded that nanoparticulate-entrapped paclitaxel was able to suppress tumor growth by killing tumor cells directly and through inhibition of angiogenesis.

This work is detailed in a paper titled, “In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors.” Based in part on these results, the NCI is now funding further work with a tumor-targeted version of this nanoparticle to determine if it can be used to overcome drug resistance in breast cancer patients. An abstract of this paper is available through PubMed.

Source: National Cancer Institute

Explore further: Medical nanoparticles: local treatment of lung cancer

add to favorites email to friend print save as pdf

Related Stories

How scorpion venom could yield new cancer treatment

Jan 07, 2015

In the development of new drugs, taking something from nature and modifying it has been a successful tactic employed by medicinal chemists for years. Now, with the help of nanotechnology, researchers are ...

Gold nanoparticles: A new delivery for cancer drugs

May 08, 2013

(Phys.org) —The protein tumor necrosis factor-alpha (TNF-alpha) is a powerful weapon in the arsenal to control cancer. Unfortunately, as is the case with many potent cancer therapies, the use of TNF-alpha as an anti-cancer ...

Improved nanoparticles deliver drugs into brain

Sep 11, 2012

The brain is a notoriously difficult organ to treat, but Johns Hopkins researchers report they are one step closer to having a drug-delivery system flexible enough to overcome some key challenges posed by ...

Recommended for you

Medical nanoparticles: local treatment of lung cancer

Mar 05, 2015

Nanoparticles can function as carriers for medicines to combat lung cancer: Working in a joint project at the NIM (Nanosystems Initiative Munich) Excellence Cluster, scientists from the Helmholtz Zentrum ...

New nanodevice defeats drug resistance

Mar 02, 2015

Chemotherapy often shrinks tumors at first, but as cancer cells become resistant to drug treatment, tumors can grow back. A new nanodevice developed by MIT researchers can help overcome that by first blocking ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.